Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease

Parker, Victoria E. R.; Hoang, Thuong; Schlichthaar, Heike; Gibb, Fraser W.; Wenzel, Barbara; Posch, Maximillian G.; Rose, Ludger; Chang, Yi‐Ting; Petrone, Marcella; Hansen, Lars; Ambery, Philip; Jermutus, Lutz; Heerspink, Hiddo J. L.; McCrimmon, Rory J.

doi:10.1111/dom.14712

Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease

Aim To assess the efficacy, safety and tolerability of cotadutide in patients with type 2 diabetes mellitus and chronic kidney disease. Materials and Methods In this phase 2a study (NCT03550378), patients with body mass index 25‐45 kg/m 2 , estimated glomerular filtration rate 30‐59 ml/min/1.73 m…